Upadacitinib (Rinvoq)
Also discussed as: upadacitinib, rinvoq, Rinvoq, RINVOQ
STRONG EVIDENCE
13 level-I · 12 level-II · 7 level-IV · 1 level-III · 2 level-VII
Research base (design-resolved): 13 systematic review/meta-analysis, 12 randomized trials, 8 observational/descriptive.
moderate · 3,794 mentions
Most discussed for: biologic, oral_medication, topical_prescription
What the research says
Upadacitinib performed best in IGA-0/1 and EASI outcomes.
Liao et al. (2025), PLoS ONE. doi:10.1371/journal.pone.0319400 · verifiedUpadacitinib exhibited > 40-, 130-, and 190-fold greater selectivity for JAK1 versus JAK2, JAK3, and TYK2.
Morelli et al. (2024), Frontiers in Immunology. doi:10.3389/fimmu.2024.1393799 · verifiedUpadacitinib treatment resulted in significant EASI-75 and EASI-90 response rates compared to placebo.
Zheng et al. (2024), Frontiers in Immunology. doi:10.3389/fimmu.2024.1367099 · verifiedUpadacitinib demonstrated higher efficacy compared to placebo.
Makowska et al. (2023), International Journal of Molecular Sciences. doi:10.3390/ijms24010781 · verifiedUpadacitinib 30 mg is the most effective among all included JAK inhibitors. (n=4367)
Tampa et al. (2023), Journal of Personalized Medicine. doi:10.3390/jpm13030384 · verifiedAchieved EASI-75 as early as week 2.
Tsuji et al. (2023), Biomedicines. doi:10.3390/biomedicines11051303 · verifiedUpadacitinib has shown promising results in the treatment of atopic dermatitis. (n=4)
Sadowsky et al. (2023), Journal of Clinical Medicine. doi:10.3390/jcm12175534 · verifiedWhat the community reports
Experience reports, not evidence. Volumes from 1.1M triaged posts.
- biologic
- oral_medication
- topical_prescription
- other
Safety and side effects
There are several reported safety concerns associated with upadacitinib, including upper respiratory tract infections and serious infections, which may occur more frequently than with some other treatments.
For infants and children
Upadacitinib is approved for use in adolescents aged 12 years and older.
Studied protocols
As reported in the papers, not recommendations.
route: oral; duration: 16 weeks
Howell et al. (2019), Frontiers in Immunologyroute: oral
Szilveszter et al. (2019), Frontiers in Immunologydose: 7.5 mg, 15 mg, 30 mg; frequency: once daily; route: oral; duration: 16 weeks
Szalus et al. (2020), Microorganismsdose: 15 mg and 30 mg; frequency: once daily; route: oral; duration: 16 weeks
Makowska et al. (2023), International Journal of Molecular Sciencesdose: 15 mg; frequency: daily; route: oral; duration: 24 weeks
Hagino et al. (2023), Journal of Clinical Medicinedose: 30 mg; frequency: once daily; route: oral
Tampa et al. (2023), Journal of Personalized MedicineDrawn from 34 papers · generated 2026-06-11T12:41:14.012077+00:00 · phrasing by gpt-4o-mini, every number computed from the database and every citation machine-verified.